Pharmacogenetic study of Fc?RIIIa and HER2 genes in relation to treatment of breast cancer - HER2 PG study
Phase 1
- Conditions
- Breast cancer.MedDRA version: 8.1Level: LLTClassification code 10006203Term: Breast cancer stage unspecified
- Registration Number
- EUCTR2006-002532-24-GB
- Lead Sponsor
- ewcastle upon Tyne Hospitals NHS Foundation Trust
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 750
Inclusion Criteria
a) Aged 18 years or over.
b) Histological confirmation of primary breast cancer with HER2 testing.
c) Written voluntary informed consent.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
a) Under the age of 18 years.
b) Unable to give informed consent.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method